We found that BCR-ABL expression in SPOA treated CML cells, either imatinib sensitive or resistant cells, began to sharp down at 9 h, and was almost undetectable at 24 h. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.